Phillip Levy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Phillip Levy has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Neelima Penugonda
2 shared publications- A Hsu
10The Cleveland Clinic, 9500 Euclid Avenue,Cleveland OH, 44195 USA
1 shared publication A. Hexdall
Bellevue Hospital Center/NYU Medical Center, New York, New YorkUSA
1 shared publication- Abhinav Chandra
Division of Emergency Medicine, Duke University Medical Center, Durham, NC, 27710 USA
1 shared publication Alison Jennett
1 shared publication- Brian Hiestand
Wake Forest School of Medicine
1 shared publication
Latest Publications
- 1 January 2012
- Published by Springer Nature
- p. 1014-1020
Heart Failure Syndromes, Treatment
- Open Access
- 27 June 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (3) , R157
CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department
Introduction: Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension. Methods: Multicenter randomized clinical trial. Eligible patients had 2 systolic blood pressure (SBP) measures ≥180 mmHg and no contraindications to nicardipine or labetalol. Before randomization, the physician specified a target SBP ± 20 mmHg (the target range: TR). The primary endpoint was the percent of subjects meeting TR during the initial 30 minutes of treatment. Results: Of 226 randomized patients, 110 received nicardipine and 116 labetalol. End organ damage preceded treatment in 143 (63.3%); 71 nicardipine and 72 labetalol patients. Median initial SBP was 212.5 (IQR 197, 230) and 212 mmHg (IQR 200,225) for nicardipine and labetalol patients (P = 0.68), respectively. Within 30 minutes, nicardipine patients more often reached TR than labetalol (91.7 vs. 82.5%, P = 0.039). Of 6 BP measures (taken every 5 minutes) during the study period, nicardipine patients had higher rates of five and six instances within TR than labetalol (47.3% vs. 32.8%, P = 0.026). Rescue medication need did not differ between nicardipine and labetalol (15.5 vs. 22.4%, P = 0.183). Labetalol patients had slower heart rates at all time points (P < 0.01). Multivariable modeling showed nicardipine patients were more likely in TR than labetalol patients at 30 minutes (OR 2.73, P = 0.028; C stat for model = 0.72) Conclusions: Patients treated with nicardipine are more likely to reach the physician-specified SBP target range within 30 minutes than those treated with labetalol. Trial registration: ClinicalTrials.gov: NCT00765648
- 27 June 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (3) , R157
Open AccessCLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department
Introduction: Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension. Methods: Multicenter randomized clinical trial. Eligible patients had 2 systolic blood pressure (SBP) measures ≥180 mmHg and no contraindications to nicardipine or labetalol. Before randomization, the physician specified a target SBP ± 20 mmHg (the target range: TR). The primary endpoint was the percent of subjects meeting TR during the initial 30 minutes of treatment. Results: Of 226 randomized patients, 110 received nicardipine and 116 labetalol. End organ damage preceded treatment in 143 (63.3%); 71 nicardipine and 72 labetalol patients. Median initial SBP was 212.5 (IQR 197, 230) and 212 mmHg (IQR 200,225) for nicardipine and labetalol patients (P = 0.68), respectively. Within 30 minutes, nicardipine patients more often reached TR than labetalol (91.7 vs. 82.5%, P = 0.039). Of 6 BP measures (taken every 5 minutes) during the study period, nicardipine patients had higher rates of five and six instances within TR than labetalol (47.3% vs. 32.8%, P = 0.026). Rescue medication need did not differ between nicardipine and labetalol (15.5 vs. 22.4%, P = 0.183). Labetalol patients had slower heart rates at all time points (P < 0.01). Multivariable modeling showed nicardipine patients were more likely in TR than labetalol patients at 30 minutes (OR 2.73, P = 0.028; C stat for model = 0.72) Conclusions: Patients treated with nicardipine are more likely to reach the physician-specified SBP target range within 30 minutes than those treated with labetalol. Trial registration: ClinicalTrials.gov: NCT00765648
- 1 March 2008
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 51 (3) , 247-250
Treatment of Massive Fluid Overload as a Result of Constrictive Pericarditis With Ultrafiltration in the Emergency Department
- 1 March 2008
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 51 (3) , 247-250
Treatment of Massive Fluid Overload as a Result of Constrictive Pericarditis With Ultrafiltration in the Emergency Department
- 1 August 2007
- Published by SAGE Publications in Disease Management
- Vol. 10 (4) , 235-244
Paying for Disease Management
Disease Management (DM) first appeared in the United States in the early 1990s. Since then its incorporation into health plans has increased dramatically, yet proof of its effectiveness in terms of quality improvement and cost reduction remains to be seen. The following review provides an exploratory analysis of the basic principles of DM, its evolution and differences from traditional managed care, the ways in which programs are currently being used in the private and public sectors, and the challenges to determining a payment structure for incorporating DM into the current health insurance system. (Disease Management 2007;10:235–244)
- 1 August 2007
- Published by SAGE Publications in Disease Management
- Vol. 10 (4) , 235-244
Paying for Disease Management
Disease Management (DM) first appeared in the United States in the early 1990s. Since then its incorporation into health plans has increased dramatically, yet proof of its effectiveness in terms of quality improvement and cost reduction remains to be seen. The following review provides an exploratory analysis of the basic principles of DM, its evolution and differences from traditional managed care, the ways in which programs are currently being used in the private and public sectors, and the challenges to determining a payment structure for incorporating DM into the current health insurance system. (Disease Management 2007;10:235–244)
- 1 August 2007
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 50 (2) , 144-152
Treatment of Severe Decompensated Heart Failure With High-Dose Intravenous Nitroglycerin: A Feasibility and Outcome Analysis
- 1 August 2007
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 50 (2) , 144-152
Treatment of Severe Decompensated Heart Failure With High-Dose Intravenous Nitroglycerin: A Feasibility and Outcome Analysis
- 1 July 2003
- Published by Wiley in Academic Emergency Medicine
- Vol. 10 (7) , 819-821
Emergency Bedside Ultrasound to Detect Pneumothorax
- 1 July 2003
- Published by Wiley in Academic Emergency Medicine
- Vol. 10 (7) , 819-821
Emergency Bedside Ultrasound to Detect Pneumothorax
- 1 January 2003
- Published by Taylor & Francis in Journal of Toxicology: Clinical Toxicology
- Vol. 41 (1) , 23-28
Methanol Contamination of Romanian Home-Distilled Alcohol
Epidemic methanol poisoning from the consumption of illicitly manufactured alcohol is a well-recognized entity within the United States [1][2]. Although large-scale toxicity was a common occurrence...
- 1 January 2003
- Published by Taylor & Francis in Journal of Toxicology: Clinical Toxicology
- Vol. 41 (1) , 23-28
Methanol Contamination of Romanian Home-Distilled Alcohol
Epidemic methanol poisoning from the consumption of illicitly manufactured alcohol is a well-recognized entity within the United States [1][2]. Although large-scale toxicity was a common occurrence...